Press Releases

PTC Therapeutics, Inc. is committed to serving the interests of all our stakeholders.
Danya
Living with
Duchenne Muscular Dystrophy,
Ukraine
DANYA - Duchenne Muscular Dysthropy- Ukraine

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.


Date Title and Summary View
Dec 06, 2021 Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery
SOUTH PLAINFIELD, N.J. , Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi ® (risdiplam) has received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its life-saving impact.
Dec 02, 2021 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Dec. 2, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 29, 2021 , the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock and 21,550 restricted stock units ("RSUs"), each
Nov 16, 2021 PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
SOUTH PLAINFIELD, N.J. , Nov. 16, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET . The presentation will be webcast live on the
Oct 28, 2021 PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results
- Total quarterly revenue of $139 million; 17% increase over third quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $400-$420M from $370-$390M - - Continues to advance robust clinical pipeline by initiating a fifth registration-directed trial, APHENITY Phase 3 trial of PTC923 in
Oct 26, 2021 PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
SOUTH PLAINFIELD, N.J. , Oct. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 8:00 a.m. ET . The presentation will be webcast live on the
Oct 25, 2021 PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil
SOUTH PLAINFIELD, N.J. , Oct. 25, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian National Health Surveillance Agency , ANVISA (Agência Nacional de Vigilância Sanitária), has approved the expansion of the indication of Translarna™ (ataluren) to include
Oct 14, 2021 PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results
SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, Oct.
Oct 14, 2021 PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility
-- Expansion in New Jersey supports company's robust gene therapy pipeline to address devastating rare disorders -- SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene
Oct 11, 2021 Tegsedi® Receives Innovative Drug Category Pricing in Brazil
SOUTH PLAINFIELD, N.J. , Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi ® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber) in Brazil .
Sep 29, 2021 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on Sept. 22, 2021, the company approved non-statutory stock options to purchase an aggregate of 51,400 shares of its common stock and 18,790 restricted stock units ("RSUs"), each